Showing 1851-1860 of 5846 results for "".
- Dr. Uri Geiger Named Chairman of its Board of Directors at STRATA Skin Scienceshttps://practicaldermatology.com/news/dr-uri-geiger-named-chairman-of-its-board-of-directors-at-strata-skin-sciences/2461837/Uri Geiger, PhD, is the new Chairman of the Board of Directors at STRATA Skin Sciences. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation.
- Valeant Dermatology Announces New Senior Leadership Team in Advance of SILIQ Launchhttps://practicaldermatology.com/news/valeant-dermatology-announces-new-senior-leadership-team-in-advance-of-siliq-launch/2458182/Valeant Dermatology announced a new senior leadership team, led by Bill Humphries, executive vice president and group chairman. The team includes Michael McMyne, vice president of sales; Stacey Williams, vice president of marketing; Charles Hahn,
- New PSA From American Academy of Dermatology Highlights Dangers of Tanninghttps://practicaldermatology.com/news/new-psa-from-american-academy-of-dermatology-highlights-dangers-of-tanning/2457753/As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside— and some may want to get a tan. But a new public service advertisement from the American Academy of Dermatology encourages those who are thinking of tanning to
- Report: Seborrheic Dermatitis Market Poised for Expansion through 2032https://practicaldermatology.com/news/report-seborrheic-dermatitis-market-poised-for-expansion-through-2032/2473856/The seborrheic dermatitis market has been projected to grow through 2032, according to a new report from Delveinsight. The expansion in market size coincides with the CAGR study, according to a press release. The report notes the recent approval of roflumilast foam 0.3% (ZORYVE, Arcutis) f
- Cosmetic Laser Market to Reach $14.79 Billion by 2033: Reporthttps://practicaldermatology.com/news/cosmetic-laser-market-to-reach-1479-billion-by-2033-report/2471023/The global cosmetic lasers market is projected to grow to $14.79 billion by 2033, at a compound annual growth rate (CAGR) of 14%, according to a new report from Straits Research. The analysis said the growth reflects increasing consumer interest in minimally invasive cosmetic procedures f
- NEA Promotes Eczema Awareness Month in Octoberhttps://practicaldermatology.com/news/nea-promotes-eczema-awareness-month-october/2468331/The National Eczema Association (NEA) will present Eczema Awareness Month throughout October to spread awareness about living with eczema, the organization announced in a press release. This year's awareness campaign puts eczema on display with real, up-close photos of community members' f
- Two New Options for After-Sun Care Launchedhttps://practicaldermatology.com/news/two-new-options-after-sun-care-launched/2467968/San Diego-based skincare company Terns announced today that it has launched two new after-sun care products targeting outdoor enthusiasts. The products, which include a range of creams and gels, are formulated with the proprietary Sirenas Complex, which the manufacturer said is derived f
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Study: Gene Expression Test IDs Best Patients for Adjuvant Radiation Therapyhttps://practicaldermatology.com/news/study-gene-expression-test-ids-best-patients-for-adjuvant-radiation-therapy/2462130/New research suggests that a 40-gene expression profile (40-GEP) test can help identify the best patients for adjuvant radiation therapy for cutaneous squamous cell carcinoma (cSCC). The study, whose results were presented at ASDS 2023, consisted of two merged validation cohorts f
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Derma